All In Biotech

Drug Trial Radar · NCT05588908

A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Last checked: Nov 19, 2026Latest source record: Oct 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

120

Planned (sponsor's estimate)

Start

Jun 29, 2022

Primary completion

Sep 2023

Study completion Nov 2023

Sponsor

Sponsor type
Industry
First posted
Oct 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the target dose of phase II and to evaluate the safety, tolerability, pharmacokinetics and efficacy of recombinant anti-IL-1β humanized monoclonal antibody injection at different doses in Chinese participants with acute gout.

Conditions

  • Acute Gout

Interventions

  • Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)Drug

    100 mg subcutaneous (s.c) once

  • Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib)Drug

    200 mg subcutaneous (s.c) once

  • Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 300 mg (phase Ib)Drug

    300 mg subcutaneous (s.c) once

  • Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase II)Drug

    one s.c. injection of SSGJ-613 once, on Day 1.

  • Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection low dose 300 mg (phase II)Drug

    one s.c. injection of SSGJ-613 once, on Day 1.

  • Compound Betamethasone Injection (phase II)Drug

    1 mL i.m. once on Day 1

  • Placebo (phase II)Other

    Participants will receive Placebo matching SSGJ-613 to maintain the blinding of the Investigational Medicinal Products.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From baseline through 24 weeks
  2. Phase Ib: Incidence and Severity of Abnormalities in Vital Signs/Physical Examinations, Laboratory Examinations and Other Relevant ExaminationsTime frame: From baseline through 24 weeks
  3. Phase II: The Change in Pain Intensity in the Target Joint From Baseline to 72 Hours Post Dose as Measured on a 0-100 mm Visual Analog Scale (VAS)Time frame: Baseline, at 72 hrs post-dose

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Site 02

    Wuhan, Hubei, China · Recruiting

  • Site 03

    Linyi, Shandong, China · Not yet recruiting

  • Site 01

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.